Detection of Human Papillomaviruses DNA in paired peripheral blood and cervix samples patients with cervical lesions and healthy individuals

Kamylla Conceição Gomes do Nascimento [1], ‡,

Elyda Lima [1],

Barbara Simas Chagas [1],

Zhilbelly da Mota Nunes [2],

Marconi Rêgo Barros Júnior [1],

Marcus Vinícius de Aragão Batista [3],

Antônio Roberto Lucena [4],

Jacinto da Costa Silva Neto [5],

Ana Pavla Almeida Diniz Gurgel[2], ‡,

Antonio Carlos de Freitas [1], ‡, ∗

[1] Department of Genetics; Laboratory of Molecular Studies and Experimental Therapy (LEMTE), Federal University of Pernambuco; Pernambuco, Brazil;

[2] Department of Engineering and Environment, Laboratory of Molecular Genetics (LAGEM), Federal University of Paraiba, Paraiba – Brazil;

[3] Department of Biology; Federal University of Sergipe; Sergipe, Brazil;

[4] Department of Biophysics and Radiobiology, Federal University of Pernambuco; Pernambuco, Brazil;

[5] Department of Histology; Federal University of Pernambuco; Pernambuco, Brazil.

*Correspondence: A. F.: antonio.freitas@pq.cnpq.br;
A. P. G.: anapavla@ccae.ufpb.br.

‡ These authors contributed equally to this work.

Abstract:

This study evaluated the presence of HPV DNA in the cervix and peripheral blood of women with cervical intraepithelial neoplasia (CIN I, II, and III) and healthy individuals. Overall, 139 paired peripheral blood and cervix samples of healthy women and women with CIN I, II, and III (n= 68) were tested for HPV DNA by using standard procedures. PCR-sequencing determined HPV types. Quantification of HPV16 E6 and E2 genes was performed to determine viral load and physical state. HPV DNA was detected in the cervix (21.1% in healthy individuals; 48.8-55.5% in CIN patients), blood (46.4% in healthy individuals; 44.1-77.7% in CIN patients), and paired peripheral blood and cervix samples (24% in healthy individuals; 32.5-44.4% in CIN patients). The most frequent types found in the cervix were HPV16, 18, 31, 33, 58, and 70, while HPV16, 18, 33, 58, and 66 were the most frequent types found in the blood. HPV DNA in the cervix was associated with previous sexually transmitted infections (STIs) (P=0.023; OR: 2.978; CI:1.34-7.821), HPV DNA in the blood (P=0.000; OR: 3.369; CI:3.700-18.540), and cervical lesions (CIN I/II or III) (P=0.001; OR: 3.369; CI:1.634-6.945). Binomial Logistic regression showed that HPV DNA in the blood (P=0.000; OR: 9.324; CI:3.612-24.072) and cervical lesions (P=0.011; OR: 3.622; CI:1.338-9.806) were associated with HPV DNA in the cervix. However, we did not find an association between HPV DNA in blood and cervical lesions (P=0.385). Our results showed that, although there is an association between HPV DNA in the cervix with HPV DNA in blood, only HPV DNA found in the cervix was associated with cervical lesions.

Keywords: HPV DNA; Cervix; Peripheral Blood; Cervical lesions; Healthy individuals.

1. Introduction

Cervical cancer is the fourth most common malignancy diagnosed in women worldwide, accounting for 6.6% of women's total cancer cases [1]. Nearly 90% of deaths caused by cervical cancer occur in women from middle and low-income countries [1].

It is well established that persistent infection caused by Human Papillomaviruses (HPV) is involved in cervical and head and neck carcinogenesis [2–9]. Despite the advances in vaccination, treatment, and monitoring, cervical cancer is still a significant cause of death in middle and low-income developing countries [1]. Hence, there is a need for minimally invasive biomarkers to monitor cervical cancer and cervical lesions. Recent studies have shown that circulating free DNA (cfDNA) or circulating tumor DNA (ctDNA) may be useful tools for monitoring cancers caused by HPV [10–16]. In this scenario, several studies have demonstrated the presence of HPV DNA in peripheral blood mononuclear cells [17–25], serum [26,27], and plasma [28–30] from cervical cancer and non-cervical cancer patients. However, despite its importance, few studies evaluate the HPV DNA in paired peripheral blood and HPV DNA in cervix samples from precancerous cervical patients and healthy individuals [21–24,30–32]. Thus, this study evaluated the prevalence of HPV DNA and viral load in paired peripheral blood and cervix samples in cervical intraepithelial neoplasia (CIN I, II, and III) patients and healthy individuals.

2. Materials and Methods

2.1. Patients

The paired cervix and blood samples were obtained from women during their gynecological consultation at Hospital das Clínicas, Pernambuco State, Northeast Brazil. The samples were collected from November 2010 to December 2016. A total of 139 women agreed and signed free and informed consent forms. This study was approved by

the Ethics and Research Committee (CAAE: 0058.0.106.000-10, HUOC/PROCAPE 64/2010) and (CEP/CCS/UFPE under CAAE: 09307612.8.0000.5208). In this study, 139 paired cervix and blood samples from 71 (51%) healthy individuals, 43 (31%) patients with cervical intraepithelial cervical grade I (CIN I), 16 (11.5%) patients with cervical intraepithelial cervical grade II (CIN II) and 9 (6.5%) patients with cervical intraepithelial cervical grade III (CIN III) were examined. Cervical cancer samples (paired cervix and blood samples) were excluded due to possible metastasis processes.

2.2.HPV DNA cervix and blood samples

DNA from cervical and peripheral blood was extracted using the DNeasy Blood & Tissue Kit (QIAGEN GmbH, Hilden, Germany), following the manufacturer's instructions. Subsequently, all samples were quantified using a spectrophotometer (NanoVue Plus Spectrophotometer). DNA quality was confirmed by polymerase chain reaction (PCR), which amplifies a fragment of the β-globin gene with the primers described in Table 1.

The presence of HPV DNA was assessed by amplification with two sets of oligonucleotides. The first step was performed with the set of consensus and degenerate primers MY09/11 (Table 1), which anneal in a conserved region of the L1 gene, amplifying a product of approximately 450 bp. Subsequently, nested-PCR was performed using oligonucleotides GP05/06, generating a fragment of approximately 140 bp. The cloned HPV 16 genome and HPV-positive cervical cancer samples were used as positive controls in all PCR reactions. Besides, all tests were performed in triplicate.

HPV-positive samples were genotyped by PCR/sequencing. PCR products were sequenced by the dideoxy-terminal fluorescent method by using the ABI PRISM BigDyeTM Terminator Cycle Sequencing v 3.1 Ready Reaction kit (Applied Biosystems,

USA). The sequences were analyzed using the Staden package (STADEN, 1996), with the programs Gap4 (version 4.0) and Pregap4 (version 1.5), which were used to assembly the contigs of the sequences obtained from HPV DNA. After the contig assembly, the BLAST program, available at http://blast.ncbi.nlm.nih.gov/Blast.cgi, was used to compare with previously known HPV sequences.

2.3. Viral load and physical status

To determine the viral load and physical status of HPV 16 positive patients, real-time PCR (qPCR) was performed by using the Sybr Green system. For this, seven random paired cervix and blood samples derived from CIN I, II, and III and 12 patients with normal cervical cytology were selected. Viral load was determined from the E6 gene levels present in all patient groups. Each sample's viral load was expressed as the number of copies of E6 in 50 ng of DNA [33]. A series of dilutions of the complete HPV genome cloned into the pBR-322 vector was carried out to generate the standard curve. Calibration curves for the E2 and E6 genes were created by using the standard dilutions. The DNA extracted from CaSki and SiHa cell lineages was used as a positive control for the reactions. Once calibration curves were constructed for each gene, the samples were analyzed in duplicate. As for physical status, the virus was considered integrated into the host genome when the E2 gene was not detected. To differentiate the episomal form from the mixed form (where there is the presence of both episomal and integrated forms), the E2/E6 ratio was calculated, in which E2/E6 ratio < 1 indicates the mixed form, and values > 1 indicate the predominance of the episomal form [33].

2.4.Statistical analysis

Clinical characteristics were compared between patients with HPV DNA positive and negative in the cervix by using chi-square and Fisher's exact tests. We performed hierarchical binary logistic regression analysis to identify the variables associated with HPV positive in the cervix, HPV DNA in blood, and cervical lesions. The correlation of viral load of HPV16 DNA in paired cervical and blood samples was examined using the Pearson correlation coefficient test. All P-values were two-sided with a significance level of 0.05, except the Pearson correlation. All data were analyzed using SPSS version 26 (SPSS Inc.Illinois, USA).

3. Results

3.1.HPV DNA detection in cervix and blood samples

Regarding the cervix or peripheral blood samples, HPV DNA was detected in 50.7% of healthy individuals, 60% in CIN I, 75% in CIN II, and 88.8% in CIN III patients. In contrast, HPV DNA in the cervix was detected in 21.1% of healthy individuals, 48.8% in CIN I, 56% in CIN II, and 55.5% in CIN III patients. In peripheral blood, HPV DNA was found in 46.4% of healthy individuals, 44.1% in CIN I, 50% in CIN II, and 77.7% in CIN III patients. In paired cervix and peripheral blood samples, HPV DNA was found in 24% of healthy individuals, 32.5% in CIN I, 38% in CIN II, and 44% in CIN III patients (Figure 1).

The most frequently found genotypes in the cervix were HPV16, 18, 31, 33, 58, and 70, while HPV16, 18, 33, 58, and 66 were the most frequently found blood sample types. Globally, the genotypes most frequently found were HPV16 and HPV58 in both cervix and peripheral blood samples. Also, HPV16 was the most frequent genotype in the paired cervix and blood samples (Table 2).

HPV DNA in cervix were associated with previous STIs (P=0.023; OR: 2.978; CI:1.34-7.821), HPV DNA in blood (P=0.000; OR: 3.369; CI:3.700-18.540) and cervical lesions (P=0.001; OR: 3.369; CI:1.634-6.945) (Table 3). Binomial Logistic regression showed that HPV DNA in the blood (P=0.000; OR: 9.324; CI:3.612-24.072) and cervical lesions (P=0.011; OR: 3.622; CI:1.338-9.806) were associated with HPV DNA in the cervix (Table 4). In contrast, HPV DNA in cervix (P=0.011; OR: 3.918; CI:1.366-11.239) and previous STIs (P=0.002; OR: 28.599; CI:3.574-228.846) were associated with cervical lesions, but not with HPV DNA in blood (P=0.385) (Tables 5 and 6).

3.2.Evaluation of viral load in paired cervix/blood tissues

According to the genotyping results, HPV16 was the best candidate to examine the viral load in the paired cervix and peripheral blood samples. Cervix and peripheral blood samples from 12 patients with CIN I, II, and III, and 17 healthy individuals were selected for viral load quantification. Regarding the CIN patients, the viral load varied from 3.65 to 21.58 (E6 copies/cell) in blood and 0.2 to 138 (E6 copies/cell) in the cervix. A correlation was observed between HPV16 viral load present in the cervix and peripheral blood samples in patients with CIN II/III (r=0.65) and CIN III (r=0.60) (Figure 3).

It was also not observed integrated physical status in blood samples from CIN patients. A positive correlation between HPV DNA viral load in cervix and blood was also observed in samples from women with the integrated or mixed virus in the cervix (r=0.64) and in mixed in their peripheral blood (r=0.66) (Figure 4).

Regarding the healthy individuals, the viral load varied from 2.76 to 83.89 (E6 copies/cell) in blood and 0.12 to 246 (E6 copies/cell) in the cervix. The integrated, episomal, and mixed physical status were observed in peripheral blood and cervix

samples. There was no correlation between HPV DNA viral load in the cervix and peripheral blood samples in healthy patients.

4. Discussion

Here, we investigated the presence of HPV DNA in paired peripheral blood and cervix samples from women with cervical lesions and healthy women. The results showed the presence of HPV DNA in the cervix and peripheral blood samples of both healthy individuals and CIN patients. Our results showed that HPV DNA found in peripheral blood was associated with HPV DNA in the cervix, but not with cervical lesions. Besides, we found a positive correlation between HPV16 viral load in the paired cervix and blood samples in women according to CIN grade and physical status of the virus in the cervix and blood. Therefore, our results showed that, although there is an association between HPV DNA in the cervix with HPV DNA in blood, only HPV DNA found in the cervix was associated with cervical lesions.

Several studies have demonstrated the presence of HPV DNA in peripheral blood mononuclear cells [17–25], serum [26,27], and plasma [28–30] from cervical cancer and non-cervical cancer patients [17–25,27–31,34–36]. According to these studies, the prevalence of HPV DNA in blood ranged from 6.9% to 87%. The studied population, type of lesion, the methodology used to detect HPV DNA, and the specimen type (serum, plasma, and peripheral blood) may reflect the HPV DNA prevalence variation in peripheral blood. In our study, we found a high prevalence of HPV DNA in the blood of patients with cervical lesions from Northeastern Brazil, where diseases caused by HPV are a significant public health concern. Also, we observed a direct relationship between the increase of HPV DNA in blood and the severity of the lesions in patients with CIN I (44.1%), II (50%), and III (77.7%). Similar results were observed in previous studies

regarding patients with cervical lesions [28,30]. We used PCR-sequencing to detect HPV DNA in whole peripheral blood and HPV DNA in the cervix. Although PCR-sequencing failed to detect multiple HPV types, this methodology is suitable for HPV DNA detection.

In our study, we detected HPV DNA in peripheral blood. However, we could not distinguish whether HPV DNA is from circulating free HPV DNA or immune cells carrying HPV DNA. Despite the importance, few studies discuss the role of the presence of HPV DNA in the blood of healthy subjects [22,24,32]. HPV DNA has also been detected in pediatric patients [22,37], healthy blood donors [22,23,32], and normal smears [25,30]. Here we observed HPV DNA in 24% of the paired cervix and blood samples from non-cervical lesion patients. When put together, these findings confirm the presence of HPV in blood from subjects with no cervical HPV infection history. However, it is not possible to exclude that the high HPV DNA prevalence in healthy individuals is due to HPV infection in other body sites.

The relationship between HPV viral load and cervical cancer severity is well established. However, few studies evaluated the viral load of HPV DNA in blood from cervical lesions patients. In this study, we observed a positive correlation between the viral load in the paired cervix and blood samples, according to the severity of the lesions (r=0.65, CIN II/III; R=0.6, CIN III), i.e., the viral load in blood increases according to the severity of the cervical lesion. Similarly, a correlation between HPV DNA in blood with the severity or tumor size was also observed in cervical [11,17,27,38–40], head and neck [41–43], lung [20], and breast cancers [44], although a study has failed in finding similar results [30].

One of the HPV-induced process's key events is the integration of the virus's genome into the host's genome [45]. The state of integration is fundamental for the initiation of viral replication. One clue that HPV DNA is integrated into the host genome

is the loss of E2. Therefore, absolute quantification of the E2 gene was performed, aiming to determine the viral genome's physical status in peripheral blood samples from patients with cervical lesions and healthy individuals. Both groups presented predominance of the mixed form. However, previous studies have reported a predominance for integrated [39] and episomal forms [22]. The virus's presence in mixed form and with a high viral load in healthy individuals reinforces the hypothesis that the virus is carried by the blood cells. Further studies are needed to clarify this aspect.

HPV DNA in peripheral blood has been historically detected in cervical cancer and non-cervical cancer tumors, in which ctHPVDNA migrates from local infection to blood (metastasis) [22]. Furthermore, recent studies have shown cfHPVDNA in the blood of cervical cancer patients [10,27,46]. HPV DNA in the blood of patients with cancer can be originated through apoptosis, necrosis, nucleosomes, phagocytosis, extracellular vesicles, HPV carrier cells, and a combination of these mechanisms [47]. However, the dissemination of HPV DNA from cervical lesions and normal smear still needs to be understood. Our study found HPV DNA in peripheral blood from both patients with and without cervical lesions. However, HPV DNA in blood was associated with HPV DNA in the cervix, but not with cervical lesions. Also, we found a positive correlation between viral load observed in the paired cervix and blood tissues. Hence, we speculated that the virus causes lesions that induce immune responses, predominantly lymphocytic, and then the cells would carry HPV DNA to other body sites through the hematogenous route. Bovine papillomavirus (BPV) cattle infected findings, a model for HPV infection study, support this hypothesis. These findings demonstrate BPV DNA presence in cattle's peripheral blood with or without warts [48-58] and your presence and activity in lymphocytes [53, 55, 57]. In cattle, studies suggest the blood like a virus reservatory [48, 53-58]. Studies in humans also support this hypothesis. Previous findings demonstrated

the presence of HPV DNA in lymphocytes, dendritic cells, NK cells, neutrophils, B lymphocytes CD20+, and CD56+ [23,24].

In conclusion, our results did not show an association between HPVDNA in blood and cervical lesions. However, more studies are needed to clarify the role of HPV DNA in blood and tumorigenesis.

Author Contributions: Conceptualization, KCGN, JCSN, APADG, ACF; methodology, KCGN, EGL, JM, ZMN, MRR, MVAB, ARL; writing–original draft preparation, KCGN, APADG, ACF; writing-review and editing, KCGN, APADG, ACF; supervision, APADG, ACF; project administration, ACF; funding acquisition, ACF.

Funding: This research was funded by Fundação de Amparo a Ciência e Tecnologia do Estado de Pernambuco (FACEPE).

Acknowledgments: Fernando Menezes Matos for technical support.

Conflicts of Interest: The authors declare no conflict of interest.

5. References

1. Martel, C.d.; Plummer, M.; Vignat, J.; Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *International Journal of Cancer* **2018**, pp. 664–670. doi:10.1002/ijc.30716@10.1002/(ISSN)1097215.world_cancer_congress2018.
2. Zur Hausen, H. Papillomavirus infections–a major cause of human cancers. *Biochimica Et Biophysica Acta* **1996**, *1288*, F55–78.
3. Zur Hausen, H. Papillomaviruses in Human Cancers. *Proceedings of the*

Association of American Physicians
1999, *111*, 581–587. doi:10.1046/j.1525-1381.1999.99723.x.

4. zur Hausen, H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. *Journal of the National Cancer Institute* **2000**, *92*, 690–698.
5. zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. *Nature Reviews Cancer* **2002**, *2*, 342–350. Number: 5 Publisher: Nature Publishing Group, doi:10.1038/nrc798.
6. Syrjänen, S. Human papillomavirus (HPV) in head and neck cancer. *Journal of Clinical Virology* **2005**, *32*, 59–66. doi:10.1016/j.jcv.2004.11.017.
7. Paz, I.B.; Cook, N.; Odom-Maryon, T.; Xie, Y.; Wilczynski, S.P. Human papillomavirus (HPV) in head and neck cancer. *Cancer* **1997**, *79*, 595–604. doi:10.1002/(SICI)1097-0142(19970201)79:3<595::AID-CNCR24>3.0.CO;2-Y.
8. Marur, S.; D'Souza, G.; Westra, W.H.; Forastiere, A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. *The Lancet Oncology* **2010**, *11*, 781–789. doi:10.1016/S1470-2045(10)70017-6.
9. Castellsagué, X.; Alemany, L.; Quer, M.; Halec, G.; Quirós, B.; Tous, S.; Clavero, O.; Alòs, L.; Biegner, T.; Szafarowski, T.; Alejo, M.; Holzinger, D.; Cadena, E.; Claros, E.; Hall, G.; Laco, J.; Poljak, M.; Benevolo, M.; Kasamatsu, E.; Mehanna, H.; Ndiaye, C.; Guimerà, N.; Lloveras, B.; León, X.; Ruiz-Cabezas, J.C.; Alvarado-Cabrero, I.; Kang, C.S.; Oh, J.K.; Garcia-Rojo, M.; Iljazovic, E.; Ajayi, O.F.; Duarte, F.; Nessa, A.; Tinoco, L.; Duran-Padilla, M.A.; Pirog, E.C.; Viarheichyk, H.; Morales, H.; Costes, V.; Félix, A.; Germar, M.J.V.; Mena, M.; Ruacan, A.; Jain, A.; Mehrotra, R.; Goodman, M.T.; Lombardi, L.E.; Ferrera, A.; Malami, S.; Albanesi, E.I.; Dabed, P.; Molina, C.; López-Revilla, R.; Mandys, V.; González, M.E.; Velasco, J.; Bravo, I.G.; Quint, W.; Pawlita, M.; Muñoz, N.; Sanjosé, S.d.; Xavier Bosch, F. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. *JNCI: Journal of the National Cancer Institute* **2016**, *108*. doi:10.1093/jnci/djv403.
10. Gu, Y.; Wan, C.; Qiu, J.; Cui, Y.; Jiang, T.; Zhuang, Z. Circulating HPV

cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis. *PLOS ONE* **2020**, *15*, e0224001. Publisher: Public Library of Science, doi:10.1371/journal.pone.0224001.

11. Kang, Z.; Stevanović, S.; Hinrichs, C.S.; Cao, L. Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring. *Clinical Cancer Research* **2017**, *23*, 6856–6862. doi:10.1158/1078-0432.CCR-17-1553.

12. Campitelli, M.; Jeannot, E.; Peter, M.; Lappartient, E.; Saada, S.; Rochefordière, A.d.l.; Fourchotte, V.; Alran, S.; Petrow, P.; Cottu, P.; Pierga, J.Y.; Lantz, O.; Couturier, J.; Sastre-Garau, X. Human Papillomavirus Mutational Insertion: Specific Marker of Circulating Tumor DNA in Cervical Cancer Patients. *PLOS ONE* **2012**, *7*, e43393. Publisher: Public Library of Science, doi:10.1371/journal.pone.0043393.

13. Leung, E.; Han, K.; Zou, J.; Zhao, Z.; Zheng, Y.; Wang, T.T.; Siu, L.L.; Pugh, T.J.; Bratman, S.V. Abstract A45: HPV sequencing facilitates ultrasensitive detection of HPV circulating tumor DNA. *Clinical Cancer Research* **2020**, *26*, A45–A45. Publisher: American Association for Cancer Research Section: Poster Presentations - Proffered Abstracts, doi:10.1158/1557-3265.LiqBiop20-A45.

14. Bernard-Tessier, A.; Jeannot, E.; Guenat, D.; Debernardi, A.; Michel, M.; Proudhon, C.; Vincent-Salomon, A.; Bièche, I.; Pierga, J.Y.; Buecher, B.; Meurisse, A.; François, E.; Cohen, R.; Jary, M.; Vendrely, V.; Samalin, E.; Hajbi, F.E.; Baba-Hamed, N.; Borg, C.; Bidard, F.C.; Kim, S. Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. *Clinical Cancer Research* **2019**, *25*, 2109–2115. Publisher: American Association for Cancer Research Section: Precision Medicine and Imaging, doi:10.1158/1078-0432.CCR-18-2984.

15. Cabel, L.; Bidard, F.C.; Servois, V.; Cacheux, W.; Mariani, P.; Romano, E.; Minsat, M.; Bieche, I.; Farkhondeh, F.; Jeannot, E.; Buecher, B. HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report. *International Journal of Cancer* **2017**, *141*, 1667–1670. _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.30863, doi:10.1002/ijc.30863.

16. Carow, K.; Gölitz, M.; Wolf, M.; Häfner, N.; Jansen, L.; Hoyer, H.; Schwarz, E.; Runnebaum, I.B.; Dürst, M. Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA. *International Journal of Molecular Sciences* **2017**, *18*, 2032. Number: 10 Publisher: Multidisciplinary Digital Publishing Institute, doi: 10.3390/ijms18102032.

17. Kay, P.; Allan, B.; Denny, L.; Hoffman, M.; Williamson, A.L. Detection of HPV 16 and HPV 18 DNA in the blood of patients with cervical cancer. *Journal of Medical Virology* **2005**, *75*, 435–439. doi:10.1002/jmv.20294.

18. Tseng, C.J.; Pao, C.C.; Lin, J.D.; Soong, Y.K.; Hong, J.H.; Hsueh, S. Detection of human papillomavirus types 16 and 18 mRNA in peripheral blood of advanced cervical cancer patients and its association with prognosis. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **1999**, *17*, 1391–1396. doi:10.1200/JCO.1999.17.5.1391.

19. Weismann, P.; Weismanova, E.; Masak, L.; Mlada, K.; Keder, D.; Ferancikova, Z.; Vizvaryova, M.; Konecny, M.; Zavodna, K.; Kausitz, J.; Benuska, J.; Repiska, V. The detection of circulating tumor cells expressing E6/E7 HR-HPV oncogenes in peripheral blood in cervical cancer patients after radical hysterectomy. *Neoplasma* **2009**, *56*, 230–238. doi:10.4149/neo_2009_03_230.

20. Chiou, H.L.; Wu, M.F.; Liaw, Y.C.; Cheng, Y.W.; Wong, R.H.; Chen, C.Y.; Lee, H. The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan. *Cancer* **2003**, *97*, 1558–1563. doi:10.1002/cncr.11191.

21. Moustafa, A.; Xie, C.; Kirkness, E.; Biggs, W.; Wong, E.; Turpaz, Y.; Bloom, K.; Delwart, E.; Nelson, K.E.; Venter, J.C.; Telenti, A. The blood DNA virome in 8,000 humans. *PLOS Pathogens* **2017**, *13*, e1006292. doi:10.1371/journal.ppat.1006292.

22. Bodaghi, S.; Wood, L.V.; Roby, G.; Ryder, C.; Steinberg, S.M.; Zheng, Z.M. Could Human Papillomaviruses Be Spread through Blood? *Journal of Clinical Microbiology* **2005**, *43*, 5428–5434. doi:10.1128/JCM.43.11.5428-5434.2005.

23. Chen, A.C.H.; Keleher, A.; Kedda, M.A.; Spurdle, A.B.; McMillan, N.A.J.; Antonsson, A. Human papillomavirus DNA detected in peripheral blood

samples from healthy Australian male blood donors. *Journal of Medical Virology* **2009**, *81*, 1792–1796. doi:10.1002/jmv.21592.

24. Foresta, C.; Bertoldo, A.; Garolla, A.; Pizzol, D.; Mason, S.; Lenzi, A.; De Toni, L. Human papillomavirus proteins are found in peripheral blood and semen Cd20+ and Cd56+ cells during Hpv-16 semen infection. *BMC Infectious Diseases* **2013**, *13*, 593. doi:10.1186/1471-2334-13-593.

25. Pao, C.C.; Lin, S.S.; Lin, C.Y.; Maa, J.S.; Lai, C.H.; Hsieh, T.T. Identification of human papillomavirus DNA sequences in peripheral blood mononuclear cells. *American Journal of Clinical Pathology* **1991**, *95*, 540–546. doi:10.1093/ajcp/95.4.540.

26. Widschwendter, A.; Brunhuber, T.; Wiedemair, A.; Mueller-Holzner, E.; Marth, C. Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history. *Journal of Clinical Virology* **2004**, *31*, 292–297. doi:10.1016/j.jcv.2004.06.009.

27. Jeannot, E.; Becette, V.; Campitelli, M.; Calméjane, M.A.; Lappartient, E.; Ruff, E.; Saada, S.; Holmes, A.; Bellet, D.; Sastre-Garau, X. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma. *The Journal of Pathology: Clinical Research* **2016**, *2*, 201–209. doi:10.1002/cjp2.47.

28. Gnanamony, M.; Peedicayil, A.; Subhashini, J.; Ram, T.S.; Rajasekar, A.; Gravitt, P.; Abraham, P. Detection and quantitation of HPV 16 and 18 in plasma of Indian women with cervical cancer. *Gynecologic Oncology* **2010**, *116*, 447–451. doi:10.1016/j.ygyno.2009.10.081.

29. Sathish, N.; Abraham, P.; Peedicayil, A.; Sridharan, G.; John, S.; Shaji, R.; Chandy, G. HPV DNA in plasma of patients with cervical carcinoma. *Journal of Clinical Virology* **2004**, *31*, 204–209. doi:10.1016/j.jcv.2004.03.013.

30. Cocuzza, C.E.; Martinelli, M.; Sina, F.; Piana, A.; Sotgiu, G.; Dell'Anna, T.; Musumeci, R. Human papillomavirus DNA detection in plasma and cervical samples of women with a recent history of low grade or precancerous cervical dysplasia. *PloS One* **2017**, *12*, e0188592. doi:10.1371/journal.pone.0188592.

31. Pao, C.; Hor, J.J.; Yang, F.p.; Lin, C.y.; Tseng, C.j. Detection of Human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis. *Journal of Clinical Oncology* **1997**, p. 1012.

32. Vergara, N.; Balanda, M.; Vidal, D.; Roldán, F.; S Martín, H.; Ramírez, E. Detection and quantitation of human papillomavirus DNA in peripheral blood mononuclear cells from blood donors. *Journal of Medical Virology* **2019**, *91*, 2009–2015. doi:10.1002/jmv.25551.

33. Peitsaro, P.; Johansson, B.; Syrjänen, S. Integrated Human Papillomavirus Type 16 Is Frequently Found in Cervical Cancer Precursors as Demonstrated by a Novel Quantitative Real-Time PCR Technique. *Journal of Clinical Microbiology* **2002**, *40*, 886–891. doi:10.1128/JCM.40.3.886-891.2002.

34. Cao, H.; Banh, A.; Kwok, S.; Shi, X.; Wu, S.; Krakow, T.; Khong, B.; Bavan, B.; Bala, R.; Pinsky, B.A.; Colevas, D.; Pourmand, N.; Koong, A.C.; Kong, C.S.; Le, Q.T. Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients. *International Journal of Radiation Oncology*Biology*Physics* **2012**, *82*, e351–e358. doi:10.1016/j.ijrobp.2011.05.061.

35. Wei, Y.C.; Chou, Y.S.; Chu, T.Y. Detection and typing of minimal human papillomavirus DNA in plasma.

International Journal of Gynecology & Obstetrics **2007**, *96*, 112–116. doi:10.1016/j.ijgo.2006.08.012.

36. Sarkola, M.E.; Grénman, S.E.; Rintala, M.a.M.; Syrjänen, K.J.; Syrjänen, S.M. Human papillomavirus in the placenta and umbilical cord blood. *Acta Obstetricia et Gynecologica Scandinavica* **2008**, *87*, 1181–1188. doi:10.1080/00016340802468308.

37. Syrjänen, S. Current concepts on human papillomavirus infections in children. *APMIS* **2010**, *118*, 494–509. doi:10.1111/j.1600-0463.2010.02620.x.

38. Dong, S.M.; Pai, S.I.; Rha, S.H.; Hildesheim, A.; Kurman, R.J.; Schwartz, P.E.; Mortel, R.; McGowan, L.; Greenberg, M.D.; Barnes, W.A.; Sidransky, D. Detection and Quantitation of Human Papillomavirus DNA in the Plasma of Patients with Cervical Carcinoma. *Cancer Epidemiology Biomarkers & Prevention* **2002**, *11*, 3–6.

39. Pornthanakasem, W.; Shotelersuk, K.; Termrungruanglert, W.; Voravud, N.; Niruthisard, S.; Mutirangura, Human papillomavirus DNA in plasma of patients with cervical cancer. *BMC Cancer* **2001**, *1*, 2. doi:10.1186/1471-2407-1-2.

40. Ho, C.M.; Yang, S.S.; Chien, T.Y.; Huang, S.H.; Jeng, C.J.; Chang, S.F. Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. *Gynecologic Oncology* **2005**, *99*, 615–621.

doi:10.1016/j.ygyno.2005.07.004.

41. Capone, R.B.; Pai, S.I.; Koch, W.M.; Gillison, M.L.; Danish, H.N.; Westra, W.H.; Daniel, R.; Shah, K.V.; Sidransky, D. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* **2000**, *6*, 4171–4175.

42. Dahlstrom, K.R.; Calzada, G.; Hanby, J.D.; Garden, A.S.; Glisson, B.S.; Li, G.; Roberts, D.B.; Weber, R.S.; Sturgis, E.M. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. *Cancer* **2013**, *119*, 81–89. doi:10.1002/cncr.27727.

43. Anayannis, N.V.; Schlecht, N.F.; Ben-Dayan, M.; Smith, R.V.; Belbin, T.J.; Ow, T.J.; Blakaj, D.M.; Burk, R.D.; Leonard, S.M.; Woodman, C.B.; Parish, J.L.; Prystowsky, M.B. Association of an intact E2 gene with higher HPV viral load, higher viral oncogene expression, and improved clinical outcome in HPV16 positive head and neck squamous cell carcinoma. *PLOS ONE* **2018**, *13*, e0191581. doi:10.1371/journal.pone.0191581.

44. Wang, T.; Zeng, X.; Li, W.; Zhu, H.; Wang, G.; Liu, X.; Lv, Y.; Wu, J.; Zhuang, X.; Zhang, J.; Zhao, Y.; Huang, H.; Fan, J.; Yao, Q.; He, C.; Zhang, X.; Huang, C.; Chen, J.; Wang, L. Detection and Analysis of Human Papillomavirus (HPV) DNA in Breast Cancer Patients by an Effective Method of HPV Capture. *PLOS ONE* **2014**, *9*, e90343. doi:10.1371/journal.pone.0090343.

45. Münger, K.; Baldwin, A.; Edwards, K.M.; Hayakawa, H.; Nguyen, C.L.; Owens, M.; Grace, M.; Huh, K. Mechanisms of Human Papillomavirus-Induced Oncogenesis. *Journal of Virology* **2004**, *78*, 11451–11460. doi:10.1128/JVI.78.21.11451-11460.2004.

46. Kang, Z.; Stevanović, S.; Hinrichs, C.S.; Cao, L. Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring. *Clinical Cancer Research* **2017**, *23*, 6856–6862. Publisher: American Association for Cancer Research Section: Personalized Medicine and Imaging, doi:10.1158/1078-0432.CCR-17-1553.

47. Keller, L.; Belloum, Y.; Wikman, H.; Pantel, K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. *British Journal of Cancer* **2020**, pp. 1–14. Publisher: Nature Publishing Group, doi:10.1038/s41416-020-01047-5.

48. Freitas, A.C.d.; Carvalho, C.d.; Brunner, O.; Birgel-Junior, E.H.; Dellalibera, A.M.M.P.; Benesi, F.J.; Gregory, L.; Beçak, W.; Santos, R.d.C.S.d. Viral DNA sequences in peripheral blood and vertical transmission of the virus: a discussion about BPV-1. *Brazilian Journal of Microbiology* **2003**, *34*, 76–78. doi:10.1590/S1517-

83822003000500026.

49. Carvalho, C.d.; Freitas, A.C.d.; Brunner, O.; Góes, L.G.B.; Cavalcante, A.Y.; Beçak, W.; Santos, R.d.C.S.d. Bovine papillomavirus type 2 in reproductive tract and gametes of slaughtered bovine females. *Braz. j. microbiol* **2003**, *34*, 82–84.

50. Yaguiu, A.; Dagli, M.L.Z.; Birgel, Jr, E.H.; Alves Reis, B.C.A.; Ferraz, O.P.; Pituco, E.M.; Freitas, A.C.; Beçak, W.; Stocco, R.C. Simultaneous presence of bovine papillomavirus and bovine leukemia virus in different bovine tissues: in situ hybridization and cytogenetic analysis. *Genetics and Molecular Research: GMR* **2008**, *7*, 487–497.

51. Silva, M.a.R.; De Albuquerque, B.M.F.; Pontes, N.E.; Coutinho, L.C.A.; Leitão, M.C.G.; Reis, M.C.; Castro, R.S.; Freitas, A.C. Detection and expression of bovine papillomavirus in blood of healthy and papillomatosis-affected cattle. *Genetics and molecular research: GMR* **2013**, *12*, 3150–3156. doi:10.4238/2013.February.28.31.

52. Brandt, S.; Schoster, A.; Tober, R.; Kainzbauer, C.; Burgstaller, J.P.; Haralambus, R.; Steinborn, R.; Hinterhofer, C.; Stanek, C. Consistent detection of bovine papillomavirus in lesions, intact skin and peripheral blood mononuclear cells of horses affected by hoof canker. *Equine Veterinary Journal* **2011**, *43*, 202–209. doi:10.1111/j.2042-3306.2010.00147.x.

53. Roperto S, Comazzi S, Ciusani E, Paolini F, Borzacchiello G, Esposito I, Lucà R, Russo V, Urraro C, Venuti A, Roperto F. PBMCs are additional sites of productive infection of bovine papillomavirus type 2. J Gen Virol. 2011 Aug;92(Pt 8):1787-1794. doi: 10.1099/vir.0.031740-0. Epub 2011 Apr 27. PMID: 21525209.

54. Roperto S, Borzacchiello G, Brun R, Leonardi L, Maiolino P, Martano M, Paciello O, Papparella S, Restucci B, Russo V, Salvatore G, Urraro C, Roperto F. A review of bovine urothelial tumours and tumour-like lesions of the urinary bladder. J Comp Pathol. 2010 Feb-Apr;142(2-3):95-108. doi: 10.1016/j.jcpa.2009.08.156. Epub 2009 Oct 8. PMID: 19818448.

55. Roperto S, Brun R, Paolini F, Urraro C, Russo V, Borzacchiello G, Pagnini U, Raso C, Rizzo C, Roperto F, Venuti A. Detection of bovine papillomavirus type 2 in the peripheral blood of cattle with urinary bladder tumours: possible biological role. J Gen Virol. 2008 Dec;89 (Pt 12):3027-3033. doi: 10.1099/vir.0.2008/004457-0. PMID: 19008389.

56. Roperto S, Russo V, Leonardi L, Martano M, Corrado F, Riccardi MG, Roperto F. Bovine Papillomavirus Type 13 Expression in the Urothelial Bladder Tumours of Cattle. Transbound Emerg Dis. 2016 Dec;63(6):628-634. doi: 10.1111/tbed.12322. Epub 2015 Jan 19. PMID: 25597262.

57. Roperto S, Russo V, Ozkul A, Sepici-Dincel A, Maiolino P, Borzacchiello G, Marcus I, Esposito I, Riccardi MG, Roperto F. Bovine papillomavirus type 2 infects the urinary bladder of water buffalo (Bubalus bubalis) and plays a crucial role in bubaline urothelial carcinogenesis. J Gen Virol. 2013 Feb;94(Pt 2):403-408. doi: 10.1099/vir.0.047662-0. Epub 2012 Oct 24. PMID: 23100367.

58. Santos EU, Silva MA, Pontes NE, Coutinho LC, Paiva SS, Castro RS, Freitas AC. Detection of Different Bovine Papillomavirus Types and Co-infection in Bloodstream of Cattle. Transbound Emerg Dis. 2016 Feb;63(1):e103-8. doi: 10.1111/tbed.12237. Epub 2014 Jun 3. PMID: 24889887.

59. Brandt, S.; Haralambus, R.; Schoster, A.; Kirnbauer, R.; Stanek, C. Peripheral blood mononuclear cells represent a reservoir of bovine papillomavirus DNA in sarcoid-affected equines. *The Journal of general virology* **2008**, *89*, 1390–1395. doi:10.1099/vir.0.83568-0.

60. de Sanjosé, S.; Serrano, B.; Tous, S.; Alejo, M.; Lloveras, B.; Quirós, B.; Clavero, O.; Vidal, A.; Ferrándiz-Pulido, C.; Pavón, M.A.; Holzinger, D.; Halec, G.; Tommasino, M.; Quint, W.; Pawlita, M.; Muñoz, N.; Bosch, F.X.; Alemany, L. Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. *JNCI Cancer Spectrum* **2019**, *2*. doi:10.1093/jncics/pky045.

61. Ciotti, M.; Giuliani, L.; Ambrogi, V.; Ronci, C.; Benedetto, A.; Mineo, T.C.; Syrjänen, K.; Favalli, C. Detection and expression of human papillomavirus oncogenes in non-small cell lung cancer. *Oncology Reports* **2006**, *16*, 183–189. doi:10.3892/or.16.1.183.

62. Gumus, M.; Yumuk, P.F.; Salepci, T.; Aliustaoglu, M.; Dane, F.; Ekenel, M.; Basaran, G.; Kaya, H.; Barisik, N.; Turhal, N.S. HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples. *Journal of experimental & clinical cancer research : CR* **2006**, *25*, 515–521.

63. Syrjänen, K.J. HPV infections and lung cancer. *Journal of Clinical Pathology* **2002**, *55*, 885–891. doi:10.1136/jcp.55.12.885.

64. Di Lonardo, A.; Venuti, A.; Marcante, M.L. Human papillomavirus in breast cancer. *Breast Cancer Research and Treatment* **1992**, *21*, 95–100. doi:10.1007/BF01836955.

65. Wilczynski, S.P.; Oft, M.; Cook, N.; Liao, S.Y.; Iftner, T. Human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix. *Human Pathology* **1993**, *24*, 96–102. doi:10.1016/0046-8177(93)90068-R.

66. Lee, Y.M.; Leu, S.Y.; Chiang, H.; Fung, C.P.; Liu, W.T. Human papillomavirus type 18 in colorectal cancer.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi **2001**, *34*, 87–91.

67. Yu, Y.; Morimoto, T.; Sasa, M.; Okazaki, K.; Harada, Y.; Fujiwara, T.; Irie, Y.; Takahashi, E.i.; Tanigami, A.; Izumi, K. Human papillomavirus type 33 DNA in breast cancer in Chinese. *Breast Cancer* **2000**, *7*, 33–36. doi:10.1007/BF02967185.

68. Klein, F.; Amin Kotb, W.F.M.; Petersen, I. Incidence of human papilloma virus in lung cancer. *Lung Cancer* **2009**, *65*, 13–18. doi:10.1016/j.lungcan.2008.10.003.

69. de Oliveira, T.H.A.; do Amaral, C.M.; de França São Marcos, B.; Nascimento, K.C.G.; de Miranda Rios, A.C.; Quixabeira, D.C.A.; Muniz, M.T.C.; Silva Neto, J.d.C.; de Freitas, A.C. Presence and activity of HPV in primary lung cancer. *Journal of Cancer Research and Clinical Oncology* **2018**, *144*, 2367–2376. doi:10.1007/s00432-018-2748-8.

70. Kroupis, C.; Markou, A.; Vourlidis, N.; Dionyssiou-Asteriou, A.; Lianidou, E.S. Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. *Clinical Biochemistry* **2006**, *39*, 727–731. doi:10.1016/j.clinbiochem.2006.03.005.



Figure 1. Prevalence of HPV in healthy individuals and CIN patients.



Figure 2. Frequency of HPV types found in the cervix and peripheral blood from women of Northeastern Brazil.



Figure 3. Correlation of HPV16 viral load between the cervix and peripheral blood samples. a - Positive correlation of HPV16 viral load between the cervix and peripheral blood samples in CIN III (r=0.6). b- Positive correlation of HPV16 viral load between the cervix and peripheral blood samples in CIN II/III patients (r=0.65).



Figure 4. Correlation of HPV16 viral load between the cervix and peripheral blood samples according to viral physical status. A - Positive correlation of HPV16 viral load between the cervix and peripheral blood samples in women with integrated or mixed viral physical status in cervix (r=0.64). B - Positive correlation of HPV16 viral load between the cervix and peripheral blood samples in women with mixed viral physical status in peripheral blood (r=0.66).

Table 1. Primers used for PCR amplification, sequencing, and viral load analysis.

Primer	**Sequence (5'→3')**	**Size (bp)**
β-globina PC04 GH20	 ACACAACTGTGTTCACTAGC CAACTTCATCCACGTTCACC	110 bp
MY09 MY11	CGTCCMARRGGAWACTGATC GCMCAGGGWCATAAYAATGG	450 bp
GP5 GP6	TTTGTTACTGTGGTAGATAC GAAAAATAAACTGTAAATCA	110 bp
E6 HPV-16 Forward Reverse	 GAGAAACTGCAATGTTTCAGGACC TGTATAGTTGTTTGCAGCTCTGTGC	81 bp
E2 HPV-16 Forward Reverse	 AACGAAGTATCCTCTCCTGAAATTATT AG CCAAGGCGACGGCTTTG	76 bp

Table 2. Clinical and histological characteristics of patients according to HPV status in the cervix.

		HPV negative (cérvice) Nº (%)	HPV Positive (cérvice) Nº (%)	*P*-value	OR (IC)
Age	<45	53 (38.1%)	31 (22,3%)		
	46-60	32 (23.0%)	20 (14,4%)		
	>60	2 (1.4%)	1 (0,7%)	0.937	
	Total	87 (62.6%)	52 (37,4%)		
Residence	Rural	13 (9.6%)	5 (3,7%)		
	Urban	72 (53.3%)	45 (33,3%)	0.382	
	Total	85 (63.0%)	50 (37,0%)		
Ethnicity	Black	15 (10.8%)	8 (5,8%)		
	Other	35 (25.2%)	24 (17,3%)		
	White	37 (26.6%)	20 (14,4%)	0.791	
	Total	87 (62.6%)	52 (37,4%)		
Age at the first sexual relation	<20	67 (48.2%)	44 (31,7%)		
	20-30	17 (12.2%)	7 (5,0%)		
	30-40	2 (1.4%)	1 (0,7%)	0.824	
	>40	1 (0.7%)	0 (0,0%)		
	Total	87 (62.6%)	52 (37,4%)		
Number of pregnancies	1	17 (16.2%)	8 (7,6%)		
	2	26 (24.8%)	10 (9,5%)		
	3	16 (15.2%)	5 (4,8%)		
	4	5 (4.8%)	4 (3,8%)		
	5	3 (2.9%)	3 (2,9%)	0.209	
	6	1 (1.0%)	3 (2,9%)		
	7	1 (1.0%)	0 (0,0%)		
	8	0 (0%)	2 (1,9%)		
	10	1 (1.0%)	0 (0,0%)		
	Total	70 (66.7%)	35 (33,3%)		
Contraceptive use	No	70 (50.4%)	43 (30,9%)		
	Yes	17 (12.2%)	9 (6,5%)	0.744	
	Total	87 (62.6%)	52 (37,4%)		
Smoking	No	70 (50.4%)	42 (30,2%)		
	Yes	10 (7.2%)	6 (4,3%)	1.00	
	Ex-smoking	7 (5.0%)	4 (2,9%)		
	Total	87 (62.6%)	52 (37,4%)		
Number of sexual partners	1	38 (29.2%)	28 (21,5%)		
	2	19 (14.6%)	9 (6,9%)		
	3	14 (10.8%)	6 (4,6%)		

	4	6 (4.6%)	3 (2,3%)	0.779	
	5	2 (1.5%)	3 (2,3%)		
	7	1 (0.8%)	0 (0,0%)		
	10	1 (0.8%)	0 (0,0%)		
	Total	81 (62.3%)	49 (37,7%)		
Previous STIs	No	67 (56.8%)	30 (25,4%)		2.978
	Yes	9 (7.6%)	12 (10,2%)	*0.023	(1.134-7.821)
	Total	76 (64.4%)	42 (35,6%)		
HPV in blood	No	60 (43.2%)	11 (7,9%)		8.283
	Yes	27 (19.4%)	41 (29,5%)	*0.000	(3.700-18.540)
	Total	87 (62.6%)	52 (37,4%)		
Cervical SILs	Without lesion	54 (38.8%)	17 12,2%		
present	NIC I	22 (15.8%)	21 (15,1%)	*0.007	
	NIC II	7 (5.0%)	9 (6,5%)		
	NIC III	4 (2.9%)	5 3,6%		

Data are presented as the number of patients and percentage.

**P*-values were calculated by chi-square test or Fisher´s exact test.

OR- Odds Ratio.

Table 3. Best predict model of HPV positive in the cervix

	B	S.E.	Wald	*P*	Odds Ratio	95% C.I Lower	95% C.I Upper
HPV in the blood (Positive)	2.233	0.484	21.289	0.000	9.324	3.612	24.072
CIN I/II or III	1.287	0.508	6.413	0.011	3.622	1.338	9.806
Previous STIs (Positive)	0.472	0.615	0.590	0.442	1.604	0.481	5.353
Constant	-2.61	0.499	27.451	0.000	0.073		

Collinearity: Tolerance>0.01; VIF<10;

Hosmer-Lemeshow: Chi-square: 6.106; *P*:0.191.

Table 4. Best predict model of HPV positive in blood.

	B	**S.E.**	**Wald**	***P***	**Odds ratio**	**95% C.I**	
						Lower	Upper
HPV in the cervix (Positive)	2.29	0.483	21.28	0.000	9.292	3.604	23.954
CIN I/II or III	-0.342	0.487	0.493	0.483			
Previous STIs (Positive)	0.129	0.627	0.042	0.837			
Constant	-0.724	0.296	6.008	0.014	0.485		

Collinearity: Toler

ance>0.01; VIF<10;

Hosmer-Lemeshow: Chi-square: 6.358; *P*:0.174.

Table 5. Best predict model of CINs

	B	S.E.	Wald	*P*	Odds Ratio	95% C.I	
						Lower	Upper
HPV in the cervix (Positive)	1.366	0.538	6.452	0.011	3.918	1.366	11.239
HPV in the blood (Positive)	-0.444	0.511	0.754	0.385			
Previous STIs (Positive)	3.353	1.061	9.988	0.002	28.599	3.574	228.846
Constant	-0.686	0.293	5.466	0.019	0.504		

Collinearity: Tolerance>0.01; VIF<10;

Hosmer-Lemeshow: Chi-square: 5.816; *P*:0.121.